Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New anti-arrhythmia agents].

P Honerjäger1, G Schmidt

  • 1Institut für Pharmakologie und Toxikologie, Technischen Universität München.

Zeitschrift Fur Kardiologie
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation, crystallization, crystal structure analysis and refinement of B-phycoerythrin from the red alga Porphyridium sordidum at 2.2 A resolution.

Journal of molecular biology·1992
Same author

[Knowledge of the Austrian pathologist Carl Sternberg (1872-1935). Attempt at a historical presentation of clinical information about lymphogranulomatosis].

Der Pathologe·1992
Same author

[Traumatic aneurysm of the hand--a rare complication of a stab injury].

Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...·1992
Same author

Is Escherichia coli invading tubuloepithelial cells?

Zentralblatt fur Bakteriologie : international journal of medical microbiology·1992
Same author

Churg-Strauss syndrome, cardiac involvement and life threatening ventricular arrhythmias.

Australian and New Zealand journal of medicine·1992
Same author

Does physical exercise influence bowel transit time in healthy young men?

The American journal of gastroenterology·1992
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[On pathogenesis of coronary heart disease].

Zeitschrift fur Kardiologie·2016
Same journal

An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis.

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Reconstructive surgery of the aortic root].

Zeitschrift fur Kardiologie·2016
See all related articles

Class-I antiarrhythmic drugs increase mortality in post-myocardial infarction patients and should be avoided. Other antiarrhythmic agents show potential but require further clinical trials for safety and efficacy in cardiac arrhythmias.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Class-I antiarrhythmic agents (encainide, flecainide, moricizine) are used for ventricular premature depolarizations.
  • Symptomatic tachyarrhythmias require careful risk-benefit assessment for class-I agents.
  • New class-I drug development appears unpromising.

Purpose of the Study:

  • Evaluate the efficacy and safety of antiarrhythmic agents.
  • Assess the impact of antiarrhythmic drugs on mortality after myocardial infarction.
  • Explore potential treatments for supraventricular and ventricular arrhythmias.

Main Methods:

  • Review of clinical trials and pharmacological profiles of antiarrhythmic drugs.
  • Analysis of mortality data in post-myocardial infarction patients treated with class-I agents.

Related Experiment Videos

  • Preclinical and clinical evaluation of class-III antiarrhythmic agents.

    • Main Results:

    • Class-I agents increase mortality in asymptomatic post-myocardial infarction patients.
    • Esmolol is an effective intravenous beta-blocker for supraventricular arrhythmias.
    • Class-III agents (sematilide, dofetilide) show preclinical efficacy but require clinical validation; torsades de pointes is a risk.

    Conclusions:

    • Avoid class-I antiarrhythmics in asymptomatic post-MI patients.
    • Amiodarone and sotalol show promise for improving survival in patients at risk of sudden cardiac death.
    • Further controlled trials are needed to establish the clinical value of new antiarrhythmic agents.